Less than one in 10 patients who could benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it publishes its initial guidance on the drugs.
Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for broader and more equitable access to these injectable treatments.
According to projections, over two billion could be obese by 2030 without intervention.
"Our latest guidance recognises that excess weight is a chronic disease that can be addressed with comprehensive and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to universal availability to the treatments that can aid individuals in losing significant body mass, says the body.
GLP-1 Therapy Shortage
Even in the present most optimistic case, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – under 10% of eligible patients, according to the health organization.
The guideline urges nations and manufacturers to increase availability, by approaches like voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Jabs Work
These medications replicate a natural hormone to delay gastric emptying, curb appetite and increase the sense of being full so users consume fewer calories.
People typically start to lose weight within a few weeks of commencing the once-weekly jabs.
Research points to patients may put most of the weight back on within a year of stopping the medication, as their normal food cravings return.
To be carrying excess weight elevates your risk for experiencing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight impacts individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
